MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer

Immune checkpoint inhibitors (ICIs) therapy elicits admirable anti-tumor responses across many types of cancer. Growing evidence point to a link to Mediator complex subunit 12 (MED12) and DNA damage repair (DDR) and TGF-β signing, while the clinical data on the association of MED12 and ICIs response...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yong, Tan, Yuan, Zhang, Qin, Duan, Qianqian, Chen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618186/
https://www.ncbi.nlm.nih.gov/pubmed/36309740
http://dx.doi.org/10.1186/s40001-022-00856-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618186/
https://www.ncbi.nlm.nih.gov/pubmed/36309740
http://dx.doi.org/10.1186/s40001-022-00856-z

Ejemplares similares